BioNTech to Report Second Quarter 2022 Financial Results and Operational Update on August 8, 2022
25 July 2022 - 08:45PM
Mainz, Germany, July 25, 2022
(GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX,
“BioNTech” or “the Company”) will announce its financial results
for the second quarter 2022 on Monday, August 8th, 2022. BioNTech
invites investors and the general public to join a conference call
and webcast with investment analysts on the same day at 8.00 a.m.
EDT (2.00 p.m. CEST) to report its financial results and provide a
corporate update for the second quarter 2022.
To access the live conference call via
telephone, please register via this link. Once registered, dial-in
numbers and a pin will be provided. It is recommended to register
at least a day in advance.
The slide presentation and audio of the webcast
will be available via this link.
Participants may also access the slides and the
webcast of the conference call via the “Events & Presentations”
page of the Investor Relations section of the Company’s website at
www.BioNTech.com. A replay of the webcast will be available shortly
after the conclusion of the call and archived on the Company’s
website for 30 days following the call.
About BioNTechBiopharmaceutical
New Technologies is a next generation immunotherapy company
pioneering novel therapies for cancer and other serious diseases.
The Company exploits a wide array of computational discovery and
therapeutic drug platforms for the rapid development of novel
biopharmaceuticals. Its broad portfolio of oncology product
candidates includes individualized and off-the-shelf mRNA-based
therapies, innovative chimeric antigen receptor T cells,
bi-specific checkpoint immuno-modulators, targeted cancer
antibodies and small molecules. Based on its deep expertise in mRNA
vaccine development and in-house manufacturing capabilities,
BioNTech and its collaborators are developing multiple mRNA vaccine
candidates for a range of infectious diseases alongside its diverse
oncology pipeline. BioNTech has established a broad set of
relationships with multiple global pharmaceutical collaborators,
including Genmab, Sanofi, Genentech, a member of the Roche Group,
Regeneron, Genevant, Fosun Pharma, and Pfizer.
For more information, please visit
www.BioNTech.com.
BioNTech Contacts
Investor RelationsSylke Maas,
Ph.D.+49 (0)6131 9084 1074Investors@biontech.de
Media RelationsJasmina
Alatovic+49 (0)6131 9084 1513Media@biontech.de
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Feb 2024 to Mar 2024
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Mar 2023 to Mar 2024